Canaccord Genuity Reiterates Buy Rating on Tandem Diabetes Care (TNDM) following Type 2 diabetes FDA clearance

February 25, 2025 10:13 AM

Canaccord Genuity analyst William Plovanic reiterated a Buy rating and $63.00 price target on Tandem Diabetes Care (NASDAQ: TNDM) after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found